Treatment of melanoma using HSV mutant

Details Treatment of melanoma using HSV mutant Treatment of melanoma using HSV mutant

2010-01-22

2011-11-29

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S231100

Reexamination Certificate

active

08067012

ABSTRACT:
Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (RL) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.

REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 6139834 (2000-10-01), Martuza et al.
patent: 6340673 (2002-01-01), Roizman et al.
patent: 2005/0226850 (2005-10-01), Brown et al.
patent: 0514603 (2002-05-01), None
patent: WO 92/04050 (1992-03-01), None
patent: WO 92/13943 (1992-08-01), None
patent: WO 93/19591 (1993-10-01), None
patent: WO 96/00007 (1996-01-01), None
patent: 96/03997 (1996-02-01), None
patent: WO 96/39841 (1996-12-01), None
patent: WO 97/12623 (1997-04-01), None
patent: 97/26904 (1997-07-01), None
patent: WO 97/26904 (1997-07-01), None
patent: 03/068809 (2003-08-01), None
patent: 2005/049844 (2005-06-01), None
patent: 2005/049845 (2005-06-01), None
patent: 2005/049846 (2005-06-01), None
patent: 2007/026146 (2007-03-01), None
patent: 2007/132169 (2007-11-01), None
patent: 2008/099189 (2008-08-01), None
patent: 2009/013448 (2009-01-01), None
Chou et al (Science, 1990, 250:1262-1266, IDS).
Davey et al (Neurosurgery, 1991, 28:8-14, IDS).
Olofsson et al (Arch. Virol., 1993, 128:241-256, IDS).
McKie et al (J of General Virology, 1994, 75:733-741, IDS).
Chou et al. (1990) Science, 250:1262-1266, “Mapping of herpes simplex virus-1 neurovirulence toγ134.5, a gene nonessential for growth in culture”.
MacLean et al. (1991) Journal of General Virology, 72:631-639, “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+between immediate early gene 1 and the ‘a’ sequence”.
von Hoff et al. (1981) The American Journal of Medicine 70(5):1027-1041, “Association Between Human Tumor Colony-Forming Assay Results and Response of An Individual Patient's Tumor to Chemotherapy”.
Kamb et al. (2007) Nature Reviews Drug Discovery 6(2):115-120, “Why is cancer drug discovery so difficult?” abstract only.
Amer, et al., “Malignant melanoma and central nervous system metastases,” Cancer, vol. 42 (1978) pp. 660-668.
Andreansky, et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,” PNAS, vol. 93 (1996) pp. 11313-11318.
Bindal, et al., “Sarcoma Metastatic to the Brain: Results of Surgical Treatment,” Neurosurgery, vol. 35(2), (Aug. 1994), pp. 185-190.
Bolovan, et al., “ICP34.5 Mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures,” Journal of Virology, (Jan. 1994) pp. 48-55.
Boviatsis, et al., “Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase,” Gene Therapy, vol. 1, (Sep. 1994) pp. 323-331.
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, vol. 247, (1990) pp. 1306-1310.
Bronner-Fraser, et al., “The Neural Crest: What can it tell us about cell migration and determination,” Current Topics in Developmental Biology, vol. 15, Chapter 1, (1980) pp. 1-25.
Budman, et al., “The current causes of death in patients with malignant melanoma,” European J. Cancer, vol. 14, (1978) pp. 327-330.
Carrel, et al., “Expression of Neuroectodermal Antigens Common to Melanomas, Gliomas and Neuroblastomas,” Acta Neuropathol. (Berlin), vol. 57, (1982) pp. 158-164.
Cassel, et al., “Newcastle disease virus as an antineoplastic agent,” Cancer, vol. 18, (1965) pp. 863-868.
Chou, J. et al., “Mapping of Herpes Simplex Virus-1 Neurovirulence to γ134.5, a Gene Nonessential for Growth in Culture,” Science, vol. 250, (1990) pp. 1262-1266.
Coen, et al., “Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate” PNAS, vol. 86, (1989) pp. 4736-4740.
Coukos, et al., “Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer,” Clinical Cancer Research, vol. 6 (Aug. 2000), pp. 3342-3353.
Dambach et al., “Oncolytic Viruses Derived from the γ34.5-Deleted Herpes Simplex Virus Recombinant R3616 Encode a Truncated UL3 Protein,” Molecular Therapy, vol. 13(5), (May 2006) pp. 891-898.
Dang, et al., “Gene Therapy and Translational Cancer Research,” Clinical Cancer Research, vol. 5 (1999) pp. 471-474.
Davey, et al., “Disposition of Cerebral Metastases from Malignant Melanoma: Implications for Radiosurgery,” Neurosurgery, vol. 28, No. 1 (1991) pp. 8-15.
DeLuca, et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4,” Journal of Virology, vol. 56(2), (Nov. 1985) pp. 558-570.
Deonarain, Mahendra “Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery,” Exp. Opin. Ther. Patents, vol. 8, (1998) pp. 53-69.
Dolan, et al., “Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17,” Journal of General Virology, vol. 73, (1992) pp. 971-973.
Goto, et al., “Oncolytic effect of newcastle disease virus on yoshida sarcoma ( I ),”Jpn. J. Microbiol., vol. 3 (1959) pp. 171-181.
Hanada, et al., “Combined Effects of Acyclovir and Human Interferon-α on Herpes Simplex Virus Replication in Cultured Neural Cells,” Journal of Medical Virology, vol. 29 (1989) pp. 7-12.
Harrington, et al., “A phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck,” Institute of Cancer Research.
Hwu, et al., “Treatment of metastatic melanoma in the brain with temozolomide and thalidomide,” The Lancet Oncology, retrieved online Jul. 3, 2009 at http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(01)00522-8/fulltext.
Javier, et al., “Genetic and Biological Analyses of a Herpes Simplex Virus Intertypic Recombinant Reduced Specifically for Neurovirulence,” Journal of Virology, vol. 61(6), (Jun. 1987) pp. 1978-1984.
Kapplitt, M.G., et al., “Mutant Herpes Simplex Virus Induced Regression of Tumours Growing in Immunocompetent Rats,” Journal of Neuro-Oncology, vol. 19, (1994) pp. 137-147.
Kesari, S., et al., “Therapy of Experimental Human Brain Tumours Using a Neuroattenuated Herpes Simplex Virus Mutant,” Laboratory Investigation, vol. 73, No. 5, (1995) pp. 636-648.
Kucharczuk, et al., “Replication-restricted Herpes Simplex Virus-based Treatment of Localized Non-CNS Malignancy,” Proc. Am. Assoc. Cancer Rest. 37:342 (1996).
Kucharczuk, et al., “Use of ‘Replication-restricted’ Herpes Virus to Treat Experimental Human malignant Mesothelioma,” Cancer Res. 57:466-471 (1997).
Lallier, Thomas E., “Cell Lineage and Cell Migration in the Neural Crest,” Cell Biology, Neuronal Migrations and Tuberous Sclerosis, Part 5, pp. 158-171.
Le Douarin, Nicole, “Migration and Differentiation of Neural Crest Cells,” Current Topics in Developmental Biology, vol. 16, Chapter 2, (1980) pp. 31-85.
Liu, et al., “ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumor properties,” Gene Therapy (2003) pp. 292-303.
Mackie, et al., “Intralesional injection of herpes simplex virus 1716 in metastatic melanoma,” The Lancet, vol. 357, (Feb. 17, 2001) pp. 525-526.
MacLean, et al

Affiliated with

Also associated with

Rating

Treatment of melanoma using HSV mutant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of melanoma using HSV mutant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of melanoma using HSV mutant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4286950